A court filing in a trademark lawsuit reveals OpenAI won't use the name “io” for its AI hardware device, which isn't expected to ship until 2027. OpenAI will not use the name “io” for its forthcoming ...

The volcanic hot spot is larger than Lake Superior, spewing eruptions six times the total energy of all of the world's power plants. Reading time 3 minutes Jupiter’s moon Io is covered in hundreds of ...

Observations from Tomorrow.io microwave sounders paired with a machine-learning intensity-estimation algorithm from the Cooperative Institute for Meteorological Satellite Studies revealed the ...

Only four months after IO Biotech decided to halve its head count, the Danish biotech is already considering whether it must resort to further layoffs. In September, IO received a knock-back from the ...

Stars are shining brighter in the Southeastern United States this week with the debut of the Michelin Guide there, the group's first-ever North American regional edition. The new guide included one ...

Robert F. Moss writes about food, drink, and travel. Based in Charleston, South Carolina, he is the Contributing Barbecue Editor for Southern Living and the author of five books on food culture and ...

The first Michelin Guide American South Ceremony will be held in Greenville, South Carolina, on November 3. The invite-only event will award Michelin Stars and other distinctions to restaurants across ...

These items were independently chosen by editors of The New York Times and Wirecutter. The Times may earn a commission on purchases through these links. No results for your selected filters. Try ...

Arriving in Rome for the first time is like being dropped into a sprawling open-air labyrinth where every path beckons. Where to start? What to prioritize? How to assure the best experiences in a ...

There are several platforms on the market that allow users to build apps without code. Bubble.io is a popular choice for no-code app building. The platform is used by teams at HubSpot, Zendesk, and ...

An experimental cancer vaccine fell short of its main objective in a Phase 3 trial in melanoma, causing shares of the shot’s developer, IO Biotech, to fall by double digits on Monday. IO Biotech, ...